Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07218874 · ClinicalTrials.gov registry record · NA

Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application

A NA study of Cancer and Solid Tumor Cancer, sponsored by University of Pittsburgh.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT07218874: Recruiting NA study of Cancer and Solid Tumor Cancer, sponsored by University of Pittsburgh.

NCT07218874 is a NA study of Cancer and Solid Tumor Cancer that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07218874, a NA study of Cancer and Solid Tumor Cancer, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

Primary Outcome

Post-intervention semi-structured interviews will be conducted to gather participant feedback and assess acceptability of the program (e.g., likelihood to keep using app and to recommend app)

Interventions

  • BEHAVIORAL Mobile Symptom Monitoring and Alert App

Study Locations (1)

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-02-02
Est. Completion 2026-12-31
Phase NA
University of Pittsburgh

1,238 total trials

What NCT07218874 shows while recruiting

NCT07218874 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Mobile Symptom Monitoring and Alert App is the first listed.

NCT07218874 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07218874 about?

NCT07218874 is a clinical study titled "Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application". The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobil...

What is the current status of trial NCT07218874?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-02-02. Estimated completion is 2026-12-31.

What conditions does trial NCT07218874 study?

This clinical trial studies the following conditions: Cancer, Solid Tumor Cancer, Chemotherapy.

What interventions are being tested in trial NCT07218874?

The interventions under investigation include: Mobile Symptom Monitoring and Alert App (BEHAVIORAL).

Who is sponsoring clinical trial NCT07218874?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07218874 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07218874's enrollment target sits among peer trials

50 422nd of 615 higher than 179 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07218874, the US trial registry maintained by the National Library of Medicine. NCT07218874 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.